| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | indisulam | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |